ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study
-
Published:2024-01
Issue:
Volume:962
Page:176202
-
ISSN:0014-2999
-
Container-title:European Journal of Pharmacology
-
language:en
-
Short-container-title:European Journal of Pharmacology
Author:
Kubota-Ishida Natsuki,
Kaji Chizuko,
Matsumoto ShogoORCID,
Wakabayashi Tsubasa,
Matsuhira Takashi,
Okura Iori,
Cho NaokiORCID,
Isshiki Satoshi,
Kumura Ko,
Tabata Yuji
Funder
Meiji Seika Pharma
Reference40 articles.
1. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP;Andoh;J. Dermatol. Sci.,2014
2. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis;Baumer;Inflamm. Allergy - Drug Targets,2007
3. Structural basis for the activity of drugs that inhibit phosphodiesterases;Card;Structure,2004
4. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis;Cheape;Expet Rev. Clin. Immunol.,2017
5. Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献